title: Activity of bacteriophages in murine tumor models depends on the route of phage administration.
abstract: Previously we investigated the anticancer activity of bacteriophage preparations in various murine tumor models. We demonstrated the antimetastatic activity of purified and nonpurified bacteriophage preparations injected intraperitoneally (IP). However, in solid tumors we observed antitumor activity of purified bacteriophages, but the lysates (raw preparations obtained by culturing phages with bacteria) stimulated tumor growth. In this article we present a comparison of the antitumor activity of bacteriophages after oral (per os, PO) and IP administration of lysates and purified preparations. Our observations indicate that PO application of a bacteriophage preparation is safer and at least as effective as IP. Stimulation of solid tumors by lysates administered orally was not observed, and bacteriophages applied PO were more effective in inhibiting metastases formation. These observations are of great importance in any consideration of possible therapeutic applications of bacteriophages. The role of the route of bacteriophage administration should be considered in the context of the effectiveness and safety of such therapies.
authors.affiliation: Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Dabrowska
authors.forename: Adam
authors.initials: A
authors.lastname: Opolski
authors.forename: Joanna
authors.initials: J
authors.lastname: Wietrzyk
authors.forename: Dmitry
authors.initials: D
authors.lastname: Nevozhay
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Szczaurska
authors.forename: Kinga
authors.initials: K
authors.lastname: Switała-Jeleń
authors.forename: Janusz
authors.initials: J
authors.lastname: Boratyński
authors.forename: Andrzej
authors.initials: A
authors.lastname: Górski
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D017122:Bacteriophage T4; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D005260:Female; D007274:Injections, Intraperitoneal; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D016896:Treatment Outcome